JP Morgan Chase’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-78
| Closed | – | – | 7473 |
|
|
2022
Q4 | $0 | Buy |
+78
| New | +$432 | ﹤0.01% | 7250 |
|
|
2022
Q3 | – | Sell |
-1,498
| Closed | -$9K | – | 7068 |
|
|
2022
Q2 | $9K | Sell |
1,498
-19,837
| -93% | -$66.8K | ﹤0.01% | 6062 |
|
|
2022
Q1 | $76K | Buy |
21,335
+12,891
| +153% | +$47.6K | ﹤0.01% | 5629 |
|
|
2021
Q4 | $42K | Buy |
+8,444
| New | +$50.9K | ﹤0.01% | 6009 |
|
|
2020
Q3 | – | Sell |
-558
| Closed | -$3K | – | 5897 |
|
|
2020
Q2 | $3K | Sell |
558
-11,815
| -95% | -$68.3K | ﹤0.01% | 5243 |
|
|
2020
Q1 | $46K | Buy |
12,373
+8,118
| +191% | +$42K | ﹤0.01% | 4753 |
|
|
2019
Q4 | $27K | Sell |
4,255
-11,075
| -72% | -$141K | ﹤0.01% | 5277 |
|
|
2019
Q3 | $215K | Buy |
15,330
+9,064
| +145% | +$149K | ﹤0.01% | 4602 |
|
|
2019
Q2 | $98K | Buy |
6,266
+1,641
| +35% | +$44K | ﹤0.01% | 4944 |
|
|
2019
Q1 | $194K | Buy |
4,625
+1,111
| +32% | +$46.8K | ﹤0.01% | 4639 |
|
|
2018
Q4 | $146K | Buy |
3,514
+336
| +11% | +$15.1K | ﹤0.01% | 4706 |
|
|
2018
Q3 | $153K | Buy |
3,178
+2,614
| +463% | +$131K | ﹤0.01% | 4787 |
|
|
2018
Q2 | $27K | Buy |
+564
| New | +$31.3K | ﹤0.01% | 5249 |
|
JP Morgan Chase's FSTX Position: Q1 2023 in Review
JP Morgan Chase sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 78 shares.
JP Morgan Chase first reported a position in FSTX in Q2 2018 and held it in 13 quarters. The position peaked at $215K in Q3 2019. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- JP Morgan Chase reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- JP Morgan Chase sold 78 F-star Therapeutics, Inc. Common Stock shares in Q1 2023.
- JP Morgan Chase first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- JP Morgan Chase's F-star Therapeutics, Inc. Common Stock position peaked at $215K in Q3 2019.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.